Panacea Biotec to produce 100 million doses of Sputnik V vaccine

The move is expected to facilitate the global supply of Sputnik V vaccine to international partners of Russian Direct Investment Fund (RDIF)

New Delhi: Panacea Biotec will produce 100 million doses per year of Sputnik V, the COVID-19 vaccine developed by the Russian Direct Investment Fund (RDIF), thereby helping to facilitate its global supply.
As per Dr. Rajesh Jain, Managing Director, Panacea Biotec, “We are pleased to collaborate with RDIF to produce Sputnik V for global markets. Panacea Biotec brings decades of vaccine manufacturing and distribution know-how to scale up Sputnik V supplies. Panacea Biotec will produce Sputnik V in its internationally accredited facilities· complying with strict GMP standards and prequalified by WHO.”
Sputnik V has been registered in 59 countries globally with a total population of over 1.5 billion people. The efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet.
The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
Kirill Dmitriev, CEO, Russian Direct Investment Fund said, “Vaccine partnerships are the only way to overcome the pandemic. The world continues its fight against coronavirus and we see a growing interest in Sputnik V vaccine as it is one of the best vaccines available. Cooperation with Panacea Biotec is an important step to produce the vaccine in India and to supply our international partners around the world.”